GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a preclinical 30 ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting ...
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-based ...
GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac litigation ...
GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...
GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal tumors, the Financial Times’ Oliver Barnes and Hannah ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback